leadf
logo-loader
viewEden Research PLC

Eden Research appoints experienced bio-agricultural entrepreneur Rob Cannings to new role of Commercial Director

Sean Smith, Eden’s chief executive officer commented: “Rob's appointment is considered a key hire within the Company's previously announced plans to grow its in-house capabilities"

Tomatoes
Most recently, Cannings served as Commercial Director at Plant Health Care with responsibility for Europe, the Middle East, Africa and Asia

Eden Research PLC (LON:EDEN) has unveiled the appointment of Rob Cannings to the new role of Commercial Director for the biopesticide products Company with immediate effect.

The AIM-listed noted that, for the last ten years, Cannings has worked in an entrepreneurial environment at the cutting edge of the agricultural biologicals industry and, prior to that, in key positions with mainstream conventional agrochemicals.

READ: Eden Research partner make first sales in Italy of breakthrough bio-pesticide

Most recently, it pointed out, Cannings served as Commercial Director at Plant Health Care with responsibility for Europe, the Middle East, Africa and Asia.

He has also been Global Product Manager for Chemtura, AgraQuest, and Bayer CropScience where he created global growth and pricing strategies for conventional and biological products and where he was instrumental in the sale of AgraQuest to Bayer for more than US$425mln, the Company added. 

Sean Smith, Eden’s chief executive officer commented: “Rob's detailed understanding of the conventional pesticide and biocontrol products markets globally will be a key asset for the company as it works towards delivering on its ambitious growth plans. 

“His hands-on experience with the entire process from research and development through to product commercialisation, marketing and sales, will be invaluable to Eden as we accelerate our growth plans by expanding our regulatory and commercial footprint.

Smith added: “Rob's appointment is considered a key hire within the Company's previously announced plans to grow its in-house capabilities through the recruitment of high-calibre staff with relevant experience and track records of demonstrable success."

In a note to clients, analysts at ‘house’ broker Shore Capital said: “We welcome the appointment of Mr Cannings and look forward to seeing further commercial progress in the future.”

In afternoon trading, shares in Eden Research held steady at 10.60p. 

 -- Adds analyst comment, share price --

Quick facts: Eden Research PLC

Price: 7.125 GBX

AIM:EDEN
Market: AIM
Market Cap: £27.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Eden Research PLC named herein, including the promotion by the Company of Eden Research PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read